The tweet was deleted by the author.
But we saved everything 🙂.
NeuroPace Inc is actively presenting its RNS System for the treatment of drug-resistant focal epilepsy at the ASSFN conference, encouraging attendees to visit Booth 107 and interact with its clinical team.
The RNS System is indicated as adjunctive therapy for adults with refractory, partial onset seizures and is offered on a prescription-only basis.
A recent study published in the Green Journal showed long-term benefits of the RNS System for patients with drug-resistant epilepsy, according to company disclosures. In the first quarter of 2026, NeuroPace reported revenue of $22.1 million, with RNS System sales growing 20% year over year and full-year guidance increased following the results. The company continues to focus on the prescription-only device as part of its commercial strategy.